The Selection of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients with High Risk for Cardiovascular Events

Keyphrases

• High Risk 100%
• Cardiovascular Risk 100%
• Type 2 Diabetes Mellitus Patients 100%
• Cardiovascular Events 100%
• Oral Antidiabetic Drugs 100%
• Multifactorial Approach 75%
• Indonesia 50%
• Type 2 Diabetes Mellitus (T2DM) 50%
• Diabetes Mellitus Type 2 50%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 50%
• Trial Outcomes 50%
• Cardiovascular Outcome Trials 50%
• Control Control 25%
• Blood Pressure 25%
• Risk Reduction 25%
• Blood Glucose 25%
• Aspirin 25%
• Dipeptidyl peptidase-4 (DPP-4) 25%
• Sulfonylurea 25%
• Metformin 25%
• Low Risk 25%
• Lipids 25%
• α-glucosidase Inhibitor 25%
• Management Guidelines 25%
• Quality Control 25%
• Quality Cost 25%
• Cost Control 25%
• Diabetes Drugs 25%
• American Diabetes Association 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Oral Antidiabetic Agent 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Acetylsalicylic Acid 50%
• Dipeptidyl Peptidase IV Inhibitor 50%
• Sulfonylurea 50%
• Metformin 50%
• Alpha-Glucosidase Inhibitor 50%

Medicine and Dentistry

• Cardiovascular System 100%
• Maturity Onset Diabetes of the Young 100%
• Oral Antidiabetic Agent 100%
• Health Care Cost 33%
• Diabetes 22%
• Blood Glucose 11%
• Acetylsalicylic Acid 11%
• Sulfonylurea 11%
• Glycon 11%
• Type 2 Diabetes 11%
• Blood Pressure 11%
• Dipeptidyl Peptidase-4 Inhibitor 11%
• Alpha-Glucosidase Inhibitor 11%